Michael L. Meyers

2.8k total citations · 1 hit paper
42 papers, 1.6k citations indexed

About

Michael L. Meyers is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael L. Meyers has authored 42 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 18 papers in Oncology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael L. Meyers's work include Histone Deacetylase Inhibitors Research (10 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Protein Degradation and Inhibitors (7 papers). Michael L. Meyers is often cited by papers focused on Histone Deacetylase Inhibitors Research (10 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Protein Degradation and Inhibitors (7 papers). Michael L. Meyers collaborates with scholars based in United States, France and Australia. Michael L. Meyers's co-authors include Alan N. Houghton, Paul B. Chapman, Katherine S. Panageas, Sanjiv S. Agarwala, Colin B. Begg, Lynn M. Schuchter, Lawrence H. Einhorn, Scott Saxman, Marc S. Ernstoff and John M. Kirkwood and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael L. Meyers

42 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

1999 542 citations Paul B. Chapman, Lawrence H. Einhorn et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Michael L. Meyers

Since Specialization

Citations

This map shows the geographic impact of Michael L. Meyers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael L. Meyers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael L. Meyers more than expected).

Fields of papers citing papers by Michael L. Meyers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael L. Meyers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael L. Meyers. The network helps show where Michael L. Meyers may publish in the future.

Co-authorship network of co-authors of Michael L. Meyers

This figure shows the co-authorship network connecting the top 25 collaborators of Michael L. Meyers. A scholar is included among the top collaborators of Michael L. Meyers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael L. Meyers. Michael L. Meyers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract A024: Genomic peroxisome proliferator-activated receptor gamma (PPARG) study: A sponsored testing program to identify patients harboring genetic alterations in advanced UC in support of the FX-909 Phase 1 study 2024 ·Clinical Cancer Research ·(unknown), Adarsh Joshi, (unknown), (unknown), Michael L. Meyers, Stefan Kirov, Evisa Gjini, Michaela Bowden	1
2	Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101) 2021 ·Blood ·Eytan M. Stein, Ibrahim Aldoss, John F. DiPersio, Richard M. Stone, Martha Arellano, Galit Rosen, Michael L. Meyers, Yifan Huang, Steve Smith, Rebecca G. Bagley, Michael J. Thirman, Manish R. Patel, Ghayas C. Issa	41
3	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy 2020 ·Clinical Cancer Research ·Matthew D. Hellmann, Pasi A. Jänne, Mateusz Opyrchal, Navid Hafez, Luis E. Raez, Dmitry I. Gabrilovich, Fang Wang, Jane B. Trepel, Min-Jung Lee, Akira Yuno, Sunmin Lee, (unknown), Serap Sankoh, Lei Wang, David Tamang, Emmett V. Schmidt, Michael L. Meyers, Suresh S. Ramalingam, Elaine Shum, Peter Ordentlich	83
4	Abstract CT072: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy 2019 ·Cancer Research ·Ryan J. Sullivan, Stergios J. Moschos, Melissa L. Johnson, Mateusz Opyrchal, Peter Ordentlich, (unknown), Serap Sankoh, Michael L. Meyers, Sanjiv S. Agarwala	31
5	Myasthenia gravis induced by avelumab 2019 ·Immunotherapy ·Carlen Yuen, Gini F. Fleming, Michael L. Meyers, Betty Soliven, Kourosh Rezania	6
6	Abstract CT072: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy 2019 ·Clinical Trials ·Ryan J. Sullivan, Stergios J. Moschos, Melissa L. Johnson, Mateusz Opyrchal, Peter Ordentlich, (unknown), Serap Sankoh, Michael L. Meyers, Sanjiv S. Agarwala	4
7	Abstract CT041: Identification of gene signatures associated with response in a Phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy 2019 ·Cancer Research ·Peter Ordentlich, Lei Wang, David Tamang, Amy Sullivan, (unknown), Dan Rozelle, Michael L. Meyers, Suresh S. Ramalingam, Matthew D. Hellmann	1
8	ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer. 2018 ·Journal of Clinical Oncology ·Nilofer S. Azad, Keisuke Shirai, Autumn J. McRee, Mateusz Opyrchal, Douglas B. Johnson, Peter Ordentlich, (unknown), Serap Sankoh, Emmett V. Schmidt, Michael L. Meyers, Melissa L. Johnson	18
9	Abstract CT179: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial 2018 ·Cancer Research ·Anthony W. Tolcher, Michael L. Meyers, Dmitry I. Gabrilovich, Fang Wang, Jane B. Trepel, Min-Jung Lee, (unknown), (unknown), Serap Sankoh, David Tamang, Peter Ordentlich	1
10	Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial 2013 ·The Lancet Oncology ·Ethan Basch, Karen A. Autio, Charles J. Ryan, Peter Mulders, Neal D. Shore, Thian Kheoh, Karim Fizazi, Christopher J. Logothetis, Dana E. Rathkopf, Matthew R. Smith, Paul N. Mainwaring, Yanni Hao, Thomas W. Griffin, Susan Li, Michael L. Meyers, Arturo Molina, Charles S. Cleeland	114
11	The Impact of Abiraterone Acetate (AA) Therapy on Patient-Reported Pain and Functional Status in Chemotherapy-Naive Patients with Progressive, Metastatic Castration-Resistant Prostate Cancer (MCRPC) 2012 ·Annals of Oncology ·Ethan Basch, Charles J. Ryan, Thian Kheoh, Karim Fizazi, C. Logothetis, Dana E. Rathkopf, Mitchell R. Smith, Paul N. Mainwaring, Yanni Hao, Thomas W. Griffin, S. Li, Michael L. Meyers, A. Molina, Charles S. Cleeland	2
12	A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer 2011 ·Cancer Investigation ·Nan Soon Wong, Kellen L. Meadows, Lee S. Rosen, Alex A. Adjei, Scott H. Kaufmann, Michael A. Morse, William P. Petros, Yali Zhu, Paul Statkevich, David L. Cutler, Michael L. Meyers, Herbert I. Hurwitz	10
13	Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer 2004 ·Journal of Clinical Oncology ·Robert Dreicer, Bruce J. Roth, Daniel P. Petrylak, David B. Agus, Michael L. Meyers, Dixie Esseltine, (unknown), (unknown), (unknown), Anthony Boral	11
14	Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer 2001 ·Urology ·Raymond C. Bergan, (unknown), Stephen K. Carter, Ivan D. Horak, William J. Slichenmyer, Michael L. Meyers	20
15	Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21 2000 ·International Journal of Cancer ·Govindaswami Ragupathi, Michael L. Meyers, Sucharita Adluri, (unknown), Cristina Musselli, Philip O. Livingston	99
16	Evaluation of CD8+ T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide 2000 ·International Journal of Cancer ·Jonathan J. Lewis, Sylvia Janetzki, (unknown), Katherine S. Panageas, Siqun Wang, Linda Williams, Michael L. Meyers, (unknown), Philip O. Livingston, Paul B. Chapman, Alan N. Houghton	91
17	Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma breakdown → 1999 ·Journal of Clinical Oncology ·Paul B. Chapman, Lawrence H. Einhorn, Michael L. Meyers, Scott Saxman, (unknown), Katherine S. Panageas, Colin B. Begg, Sanjiv S. Agarwala, Lynn M. Schuchter, Marc S. Ernstoff, Alan N. Houghton, John M. Kirkwood	542
18	Metastatic germ cell tumors: modeling for response to chemotherapy. 1998 ·Journal of Clinical Oncology ·Dean F. Bajorin, Madhu Mazumdar, Michael L. Meyers, Robert J. Motzer, Vaia Vlamis, Po‐Hung Lin, George J. Bosl	21
19	MEDICAL TREATMENT OF METASTATIC MELANOMA 1996 ·Surgical Clinics of North America ·Alan N. Houghton, Michael L. Meyers, (unknown)	19
20	Pharmacokinetics of the Cardioprotector ADR-529 (ICRF-187) in Escalating Doses Combined With Fixed-Dose Doxorubicin 1992 ·JNCI Journal of the National Cancer Institute ·Howard S. Höchster, Leonard Liebes, Scott Wadler, Ruth Oratz, J Wernz, Michael L. Meyers, Michael D. Green, Ronald H. Blum, James L. Speyer	70

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact